Comparative Pharmacology
Head-to-head clinical analysis: ATHENTIA NEXT versus ORTHO NOVUM 7 14 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATHENTIA NEXT versus ORTHO NOVUM 7 14 28.
ATHENTIA NEXT vs ORTHO-NOVUM 7/14-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a progestin that inhibits ovulation and alters cervical mucus, reducing sperm penetration. Ethinyl estradiol suppresses gonadotropin release, preventing follicular development.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrial receptivity.
Not established. ATHENTIA NEXT is not a recognized pharmaceutical agent. Consult official prescribing information.
One tablet daily for 28 days; each tablet contains norethindrone 0.5 mg and ethinyl estradiol 0.035 mg (days 1-7), norethindrone 0.75 mg and ethinyl estradiol 0.035 mg (days 8-14), norethindrone 1 mg and ethinyl estradiol 0.035 mg (days 15-21), and placebo (days 22-28). Take at same time each day.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in healthy adults; clinically relevant for once-daily dosing.
Ethinyl estradiol: ~13-27 h (mean 17 h); Norethindrone: ~5-14 h (mean 8 h). Clinical context: steady-state achieved after ~5 days; half-life supports daily dosing.
Renal excretion of unchanged drug: 60-70%; fecal/biliary elimination: 20-30%; hepatic metabolism accounts for <10%.
Renal: ~50-60% (metabolites); biliary/fecal: ~30-40% (metabolites); unchanged drug <1% in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive